CAPR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026

Faruqi & Faruqi is investigating potential securities-law claims against Capricor Therapeutics (NASDAQ: CAPR) and notes that a federal securities class action has been filed. Investors who purchased Capricor securities between December 17, 2025 and July 26, 2026 have until September 28, 2026 to seek appointment as lead plaintiff. The notice signals litigation risk for Capricor, though it provides no allegations, damages estimate, or financial impact.

Analysis

The litigation notice itself is not a fundamental catalyst; these announcements are largely claimant-solicitation events and rarely alter enterprise value absent a disclosed regulatory, clinical, or commercial failure. CAPR may nevertheless face near-term technical pressure because small-cap biotech holders often de-risk into headline uncertainty, while prospective-financing investors demand a wider discount until the underlying allegations and potential damages are clarified.

The relevant 1-3 month issue is not the September 28 lead-plaintiff deadline but whether management must revise prior statements, disclose an FDA interaction, delay a program, or raise capital below market. A secondary offering after litigation-driven weakness would be materially dilutive and could create a self-reinforcing cycle: lower share price, more warrants or shares issued, and reduced strategic-partner leverage. Conversely, a routine dismissal or absence of new company disclosures would likely make this a transient volatility event rather than a durable valuation impairment.

Avoid treating the filing as a standalone short signal. Securities suits against development-stage biotech frequently follow sharp stock declines and do not establish that the alleged conduct is economically material. The more actionable contrarian setup is to monitor whether implied volatility and borrow costs rise disproportionately to any independently verified change in clinical probability or cash runway; if they do, the legal headline could create an opportunity to sell premium rather than express a directional view.

Key Decisions for Investors

• No new directional CAPR position solely on this notice; maintain a watch alert through the September 28 lead-plaintiff deadline and subsequent company filings for restatements, program delays, FDA correspondence, or revised guidance.
• For existing long CAPR exposure, reduce gross exposure or hedge over the next 1-3 months if cash runway is under 12 months or management signals financing needs; a discounted equity raise is the key downside transmission mechanism, not the lawsuit deadline.
• Only consider a tactical short in CAPR after independently verifiable adverse disclosure or a financing announcement; use a defined-risk put spread because biotech gap risk from clinical, regulatory, or partnership news can overwhelm litigation-driven downside.
• If CAPR options implied volatility materially exceeds its post-event realized volatility without new fundamental disclosures, evaluate small defined-risk premium-selling structures after confirming liquidity, borrow conditions, cash runway, and binary clinical-event dates.